Download Naloxone (Narcan) Drug Information Classification Opioid

Naloxone (Narcan) Drug Information
Classification
Pharmacology
Indications
Contraindications
Precautions
Warnings
Dose
Route of
Administration
Onset
Duration of
Action
Metabolism and
Excretion
Storage and
Stability
Opioid antagonist
Prevents or reverses the effects of opioids by blocking the κ, σ and μ opioid
receptor sites in the central nervous system
respiratory depression
sedation
hypotension
Has no pharmacological effect in the absence of opioids:
produces withdrawal symptoms
Acute opioid overdose or complete or partial reversal of opioid depression:
respiratory depression
Hypersensitivity to naloxone or any ingredient in the formulation
o naloxone hydrochloride
o methylparaben
o propylparaben
Naloxone should be used with caution in clients with pre-existing cardiac
disease or in clients receiving potentially cardiotoxic drugs. Reports of
hypotension, hypertension, ventricular fibrillation, ventricular tachycardia,
and pulmonary edema have been reported in post-operative patients
receiving naloxone.
Pregnancy
Data is limited regarding the effects of naloxone on the fetus. Pregnancy is
not a contraindication for naloxone administration.
Lactation/Breast-Feeding
It is not known whether naloxone is excreted into human breast milk.
Consideration of the risks and benefits of administration should be applied.
Initial dose of 0.4mg followed by a repeat 0.4mg dose every 2 minutes prn.
Each THN Kit contains two 0.4mg/mL vials.
Intramuscular (IM) or Subcutaneous (SC)
2-5 minutes
Depends on the route of administration and can range from 30–120
minutes.
Individuals treated with naloxone should go to the Emergency Department.
Rapidly metabolized in the liver with a half-life of 30–60 minutes in adults.
Excreted in the urine.
Store between 15–30°C and protect from light.
Keep out of reach of children.
This resource tool has been adapted for use with permission from the B.C. Centre for Disease Control
Harm Reduction Program